These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 18042642

  • 1. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
    van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.
    Ann Rheum Dis; 2008 Apr; 67(4):563-6. PubMed ID: 18042642
    [Abstract] [Full Text] [Related]

  • 2. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M, Levarht EW, Sont JK, Huizinga TW, Toes RE, van Laar JM.
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [Abstract] [Full Text] [Related]

  • 3. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
    Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.
    Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of synovial lymphoid neogenesis and its reversal after anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD, Celis R, Moll C, Izquierdo E, Marsal S, Sanmartí R, Palacín A, Lora D, de la Cruz J, Pablos JL.
    Ann Rheum Dis; 2009 May; 68(5):751-6. PubMed ID: 18495732
    [Abstract] [Full Text] [Related]

  • 5. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
    Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
    Rheumatology (Oxford); 2008 Jun; 47(6):780-8. PubMed ID: 18388148
    [Abstract] [Full Text] [Related]

  • 6. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, British Society for Rheumatology Biologics Register.
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [Abstract] [Full Text] [Related]

  • 7. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 8. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD, Suárez B, Hernández MV, Sanmartí R, Rego I, Celis R, Moll C, Pinto JA, Blanco FJ, Lozano F.
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [Abstract] [Full Text] [Related]

  • 9. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
    De Rycke L, Vandooren B, Kruithof E, De Keyser F, Veys EM, Baeten D.
    Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
    [Abstract] [Full Text] [Related]

  • 10. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI, af Klint E, Ernestam S, Catrina SB, Makrygiannakis D, Botusan IR, Klareskog L, Ulfgren AK.
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [Abstract] [Full Text] [Related]

  • 11. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 12. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor.
    Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P.
    Arthritis Rheum; 2008 May; 58(5):1258-63. PubMed ID: 18438841
    [Abstract] [Full Text] [Related]

  • 13. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients.
    Balanescu A, Radu E, Nat R, Regalia T, Bojinca V, Ionescu R, Balanescu S, Savu C, Predeteanu D.
    Int J Clin Pharmacol Res; 2005 May; 25(1):9-18. PubMed ID: 15864873
    [Abstract] [Full Text] [Related]

  • 14. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC.
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [Abstract] [Full Text] [Related]

  • 15. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns.
    Flendrie M, Creemers MC, van Riel PL.
    Rheumatology (Oxford); 2007 Jan; 46(1):146-9. PubMed ID: 16782732
    [Abstract] [Full Text] [Related]

  • 16. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis.
    Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, Morgan S, Nash AF, Tak PP.
    Arthritis Rheum; 2004 Dec; 50(12):3783-91. PubMed ID: 15593225
    [Abstract] [Full Text] [Related]

  • 17. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN, Masding A, Somerville M, Gaffney K, Scott DG.
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [Abstract] [Full Text] [Related]

  • 18. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue.
    Smeets TJ, Kraan MC, van Loon ME, Tak PP.
    Arthritis Rheum; 2003 Aug; 48(8):2155-62. PubMed ID: 12905468
    [Abstract] [Full Text] [Related]

  • 19. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.
    Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D.
    Arthritis Rheum; 2003 Jul; 48(7):1849-52. PubMed ID: 12847678
    [Abstract] [Full Text] [Related]

  • 20. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
    Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A.
    J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.